Avoiding Electromagnetic Interference: FDA Issues Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
The draft lists nine elements, including a summary of testing and results, that FDA wants to see from manufacturers to show new electrical devices pose no electromagnetic interference risk.
You may also be interested in...
US FDA Electromagnetic Compatibility Guidance Finalized
In the final medical device electromagnetic compatibility guidance FDA clarified the scope of applications that could use this guidance and added a recommendation for sponsors to identify and consider the intended use environmental that could affect the EMC of their products.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.